Related references
Note: Only part of the references are listed.4-Sodium phenyl butyric acid has both efficacy and counter-indicative effects in the treatment of Col4a1 disease
Frances E. Jones et al.
HUMAN MOLECULAR GENETICS (2019)
Diagnostic Utility of Exome Sequencing for Kidney Disease
E. E. Groopman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model
Tsubasa Yokota et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Bardoxolone-the Phoenix?
Robert D. Toto
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Should We Increase GFR with Bardoxolone in Alport Syndrome?
Colin Baigent et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Alport syndrome: a unified classification of genetic disorders of collagen IV alpha 345: a position paper of the Alport Syndrome Classification Working Group
Clifford E. Kashtan et al.
KIDNEY INTERNATIONAL (2018)
Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice
Dominic Cosgrove et al.
KIDNEY INTERNATIONAL (2018)
Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis
Alla Mitrofanova et al.
KIDNEY INTERNATIONAL (2018)
Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome
Eun Hui Bae et al.
KIDNEY INTERNATIONAL (2017)
Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS)
Bernd Kuebler et al.
STEM CELL RESEARCH (2017)
Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS)
Bernd Kuebler et al.
STEM CELL RESEARCH (2017)
Cyclodextrins and Iatrogenic Hearing Loss: New Drugs with Significant Risk
Mark A. Crumling et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2017)
Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model
Kohei Omachi et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2017)
The Chemical Chaperone, PBA, Reduces ER Stress and Autophagy and Increases Collagen IV α5 Expression in Cultured Fibroblasts From Men With X-Linked Alport Syndrome and Missense Mutations
Dongmao Wang et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Podocyte p53 Limits the Severity of Experimental Alport Syndrome
Ryosuke Fukuda et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis
Christine Gast et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Genetic, Clinical, and Pathologic Backgrounds of Patients with Autosomal Dominant Alport Syndrome
Naohiro Kamiyoshi et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat
D. P. Germain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome
Dafni Moschidou et al.
STEM CELLS AND DEVELOPMENT (2016)
Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease
Naoki Nakagawa et al.
JCI INSIGHT (2016)
Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways
Ivan G. Gomez et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Carriers of Autosomal Recessive Alport Syndrome with Thin Basement Membrane Nephropathy Presenting as Focal Segmental Glomerulosclerosis in Later Life
Constantinos Deltas et al.
NEPHRON (2015)
Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke
Lydia S. Murray et al.
HUMAN MOLECULAR GENETICS (2014)
Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy
Michal Herman-Edelstein et al.
JOURNAL OF LIPID RESEARCH (2014)
Evidence for Activation of the Unfolded Protein Response in Collagen IV Nephropathies
Myrtani Pieri et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Feasibility of Repairing Glomerular Basement Membrane Defects in Alport Syndrome
Xiaobo Lin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2betal delays kidney fibrosis in COL4A3 knockout mice
Diana Rubel et al.
MATRIX BIOLOGY (2014)
Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis
Diana Rubel et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies
Oliver Gross et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Frequency of COL4A3/COL4A4 Mutations amongst Families Segregating Glomerular Microscopic Hematuria and Evidence for Activation of the Unfolded Protein Response. Focal and Segmental Glomerulosclerosis Is a Frequent Development during Ageing
Louiza Papazachariou et al.
PLOS ONE (2014)
Laminin 2 Gene Missense Mutation Produces Endoplasmic Reticulum Stress in Podocytes
Ying Maggie Chen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Expert Guidelines for the Management of Alport Syndrome and Thin Basement Membrane Nephropathy
Judy Savige et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Dick de Zeeuw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome
Nicholas J. A. Webb et al.
PEDIATRIC NEPHROLOGY (2013)
Diagnosis of Alport syndrome-search for proteomic biomarkers in body fluids
Michael Pohl et al.
PEDIATRIC NEPHROLOGY (2013)
Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1
Marisa Giani et al.
PEDIATRIC NEPHROLOGY (2013)
Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations
Johanna Temme et al.
KIDNEY INTERNATIONAL (2012)
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
Oliver Gross et al.
KIDNEY INTERNATIONAL (2012)
Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis
Guillaume Bollee et al.
NATURE MEDICINE (2011)
Efficacy and safety of losartan in children with Alport syndrome-results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial
Nicholas J. A. Webb et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pablo E. Pergola et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Genotype-Phenotype Correlation in X-Linked Alport Syndrome
Mir Reza Bekheirnia et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease
Oliver Gross et al.
MATRIX BIOLOGY (2010)
Cellular Origins of Type IV Collagen Networks in Developing Glomeruli
Dale R. Abrahamson et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease
Daniel T. Meehan et al.
KIDNEY INTERNATIONAL (2009)
Stem cell therapy for Alport syndrome: the hope beyond the hype
Oliver Gross et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome
Marie-Louise Koepke et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice
Ryan M. Fryer et al.
NEPHRON PHYSIOLOGY (2007)
The effect of aldosterone blockade in patients with Alport syndrome
Hiroshi Kaito et al.
PEDIATRIC NEPHROLOGY (2006)
Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice
V. Ninichuk et al.
KIDNEY INTERNATIONAL (2006)
Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease
Hikaru Sugimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The molecular basis of Goodpasture and Alport syndromes: Beacons for the discovery of the collagen IV family
BG Hudson
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
X-linked Alport syndrome:: Natural history and genotype-phenotype correlations in girls and women belonging to 195 families:: A European community Alport syndrome concerted action study
JP Jais et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Alport's syndrome, Goodpasture's syndrome, and type IV collagen
BG Hudson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome
O Gross et al.
KIDNEY INTERNATIONAL (2003)
Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling
O Gross et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enalapril in paediatric patients with Alport syndrome: 2 years' experience
W Proesmans et al.
EUROPEAN JOURNAL OF PEDIATRICS (2000)